{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:37:39Z","timestamp":1792823859537,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autosomal dominant hypophosphatemic rickets (ADHR) is a rare genetic disorder, characterized by fibroblast growth factor 23 (FGF23)-mediated renal phosphate wasting and impaired bone mineralization. Iron deficiency in ADHR increases FGF23 production and can worsen hypophosphatemia. Evidence to guide optimal management in severe adult cases remains limited. We report the use of burosumab as bridging therapy in a 19-yr-old woman with genetically confirmed ADHR (FGF23 p.Arg176Trp), severe osteomalacia, iron-deficiency anemia, and a low-energy femoral diaphyseal fracture complicated by nonunion despite conventional therapy. Treatment with burosumab resulted in rapid clinical improvement, with marked reduction in musculoskeletal pain and stiffness, and restoration of independent ambulation within four months. BMD increased substantially (+11.7% at the LS and +14.2% at the total hip at 5\u00a0mo; +63.8% and +55.5% from baseline at approximately 11\u00a0mo, respectively), while trabecular bone score remained within the normal range, a pattern consistent with improved mineralization and preserved trabecular texture. Serum phosphate increased but did not consistently normalize at trough, prompting dose escalation. At 8\u00a0mo, the burosumab dose was increased to 50\u00a0mg (1.25\u00a0mg\/kg) due to persistent hypophosphatemia; with concurrent oral iron replacement, transient hyperphosphatemia (1.61\u00a0mmol\/L) occurred and was managed by delaying the next dose by 14\u00a0d and reducing the dose back to 1\u00a0mg\/kg. The patient also underwent additional surgical intervention, which may have contributed to the overall outcome; radiographic callus formation was evident 5\u00a0mo post-surgery. To our knowledge, this is the first full-length report describing burosumab use in genetically confirmed ADHR with longitudinal biochemical and densitometric follow-up, and it highlights the importance of careful monitoring of phosphate and iron indices when combining therapies.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag151","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:51Z","timestamp":1789473891000},"source":"Crossref","is-referenced-by-count":0,"title":["Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-3527","authenticated-orcid":false,"given":"Matej","family":"Rakusa","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana , 1525 Ljubljana ,","place":["Slovenia"]},{"name":"Faculty of Medicine, University of Ljubljana , 1000 Ljubljana ,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8606-6825","authenticated-orcid":false,"given":"Tomaz","family":"Kocjan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , 1000 Ljubljana ,","place":["Slovenia"]},{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana , 1525 Ljubljana ,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"6","key":"2026102401521316700_ref1","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1046\/j.1523-1755.2001.00064.x","article-title":"Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23","volume":"60","author":"White","year":"2001","journal-title":"Kidney Int"},{"issue":"1","key":"2026102401521316700_ref2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00223-020-00692-5","article-title":"Congenital conditions of hypophosphatemia in children","volume":"108","author":"Imel","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2026102401521316700_ref3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00223-019-00597-y","article-title":"Earlier onset in autosomal dominant hypophosphatemic rickets of R179 than R176 mutations in fibroblast growth factor 23: report of 20 Chinese cases and review of the literature","volume":"105","author":"Liu","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2026102401521316700_ref4","doi-asserted-by":"publisher","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","article-title":"Rickets","volume":"3","author":"Carpenter","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"18","key":"2026102401521316700_ref5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","article-title":"Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets","volume":"303","author":"Glorieux","year":"1980","journal-title":"N Engl J Med"},{"issue":"2","key":"2026102401521316700_ref6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/jbmr.3941","article-title":"Oral iron for prevention and treatment of rickets and osteomalacia in autosomal dominant hypophosphatemia","volume":"35","author":"H\u00f6gler","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026102401521316700_ref7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jbmr.3878","article-title":"Oral iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets","volume":"35","author":"Imel","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026102401521316700_ref8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-020-05649-w","article-title":"Iron deficiency plays essential roles in the trigger, treatment, and prognosis of autosomal dominant hypophosphatemic rickets","volume":"32","author":"Liu","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026102401521316700_ref9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia","volume":"108","author":"Weber","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026102401521316700_ref10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026102401521316700_ref11","doi-asserted-by":"publisher","first-page":"EP191","DOI":"10.1530\/endoabs.110.EP191","article-title":"Successful treatment of autosomal dominant hypophosphatemic rickets with burosumab: a case report","volume":"110","author":"Rakusa","year":"2025","journal-title":"Endocr Abstr"},{"key":"2026102401521316700_ref12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","article-title":"Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia","volume":"5","author":"Ruppe","year":"2016","journal-title":"Bone Rep"},{"issue":"8","key":"2026102401521316700_ref13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of Burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026102401521316700_ref14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"23","key":"2026102401521316700_ref15","doi-asserted-by":"publisher","first-page":"14896","DOI":"10.3390\/ijms232314896","article-title":"Osteomalacia is not a single disease","volume":"23","author":"Cianferotti","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026102401521316700_ref16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00198-011-1824-6","article-title":"Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects","volume":"23","author":"Bousson","year":"2012","journal-title":"Osteoporos Int"},{"issue":"9","key":"2026102401521316700_ref17","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/jbmr.4641","article-title":"Bone matrix mineralization and response to burosumab in adult patients with X-linked hypophosphatemia: results from the phase 3, single-arm international trial","volume":"37","author":"Fratzl-Zelman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026102401521316700_ref18","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102401521316700_ref19","author":"Crysvita (burosumab-twza)","year":"2026"},{"issue":"8","key":"2026102401521316700_ref20","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag151\/71088619\/ziag151.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/11\/ziag151\/71088619\/ziag151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/11\/ziag151\/71088619\/ziag151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:52:24Z","timestamp":1792821144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag151\/8795979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag151","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,15]]},"article-number":"ziag151"}}